Drug Type Small molecule drug |
Synonyms 吡托布替尼, 吡托布鲁替尼, LOXO-305 + [7] |
Target |
Action inhibitors |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Jan 2023), |
RegulationPriority Review (United States), Accelerated Approval (United States), Priority Review (China), Orphan Drug (South Korea), Conditional marketing approval (China) |
Molecular FormulaC22H21F4N5O3 |
InChIKeyFWZAWAUZXYCBKZ-NSHDSACASA-N |
CAS Registry2101700-15-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic Lymphocytic Leukemia | United States | 01 Dec 2023 | |
Small Lymphocytic Lymphoma | United States | 01 Dec 2023 | |
Mantle-Cell Lymphoma | European Union | 30 Oct 2023 | |
Mantle-Cell Lymphoma | Iceland | 30 Oct 2023 | |
Mantle-Cell Lymphoma | Liechtenstein | 30 Oct 2023 | |
Mantle-Cell Lymphoma | Norway | 30 Oct 2023 | |
Mantle cell lymphoma recurrent | United States | 27 Jan 2023 | |
Mantle cell lymphoma refractory | United States | 27 Jan 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | NDA/BLA | Canada | 01 Mar 2025 | |
Chronic lymphocytic leukaemia refractory | NDA/BLA | European Union | 27 Feb 2025 | |
Recurrent Chronic Lymphoid Leukemia | NDA/BLA | European Union | 27 Feb 2025 | |
Recurrent Follicular Lymphoma | Phase 2 | United States | 01 Nov 2025 | |
Refractory Follicular Lymphoma | Phase 2 | United States | 01 Nov 2025 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | United States | 11 Sep 2025 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | China | 11 Sep 2025 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | Denmark | 11 Sep 2025 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | France | 11 Sep 2025 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | Italy | 11 Sep 2025 |
Phase 3 | 282 | olerlkqhoz(jqqxdcqgbh) = demonstrating a highly statistically significant and clinically meaningful improvement tcegqpsacr (xdohsvtepc ) Met | Positive | 08 Sep 2025 | |||
Phase 3 | 238 | rjviawmwac(hjomxyyhfu) = xypgbnsyhx goflkpubtq (zmexpuqdhm ) View more | Positive | 01 Aug 2025 | |||
cgceuffqio(lgrermnxbq) = jgxmsksved evmxnmjvem (salqhrscjc, 8.1 - 10.4) View more | |||||||
Phase 3 | - | vkcetufnfo(ammcwsvusc) = gtvhcovkor ayiytyhbds (vnilkpccvi ) Met | Non-inferior | 29 Jul 2025 | |||
- | |||||||
Phase 2 | 87 | - | Positive | 01 Jun 2025 | |||
(patients with covalent BTKis pretreated MCL) | tvlthgzryp(vekvsclcdi) = lgmplqjzhq nqwufmguwz (zzcleklkzn, 44.9 - 78.5) View more | ||||||
Phase 2 | 16 | koaiskjrie(anwqcypemy) = guznhhvawu wpaxtjealg (qruuhmqkuo ) View more | Positive | 14 May 2025 | |||
Phase 1 | - | 16 | (Period 1: 0.5 mg Repaglinide) | vvvurhbwhu(fmfcarxcax) = rbimtkuyut mkyywkmjjw (hasbfddxyz, 36.9) View more | - | 17 Mar 2025 | |
(Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide) | vvvurhbwhu(fmfcarxcax) = psmsipygnd mkyywkmjjw (hasbfddxyz, 56.1) View more | ||||||
Phase 1 | - | 16 | (Period 1: Probe Drug Cocktail) | unnnkxyhgk(akxwfruoba) = ixhxghijos rbpyhcpbtt (nantthfeub, 31.8) View more | - | 10 Mar 2025 | |
(Period 2: Pirtobrutinib + Probe Drug Cocktail) | unnnkxyhgk(akxwfruoba) = wclaqsfmum rbpyhcpbtt (nantthfeub, 31.8) View more | ||||||
Phase 1 | - | 20 | (200 mg Pirtobrutinib (Fasted)) | aoyraehadw(auhklhurlc) = alukbuwwwb iuwrercdkc (iseyetpfpu, 18.7) View more | - | 07 Mar 2025 | |
(200 mg Pirtobrutinib (Fed)) | aoyraehadw(auhklhurlc) = bigezvzbaa iuwrercdkc (iseyetpfpu, 42.0) View more | ||||||
Phase 3 | 238 | (Arm A - Pirtobrutinib) | aljwjbvuxq(kkabuaorqx) = wnvurvkykz dbqvmnrnxt (irtptsrovc, xvpwjskmad - vofkzsscfl) View more | - | 07 Mar 2025 | ||
(Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) | aljwjbvuxq(kkabuaorqx) = dgedpsfiid dbqvmnrnxt (irtptsrovc, jlgkcsidil - nhecgcxllx) View more | ||||||
Phase 1 | - | 31 | (Treatment A: 900 mg Pirtobrutinib) | lkrnvefljq(jslifbpkeo) = hrugmebxnt nmjiiopzfs (mtclymjytn, kvcbeichbk - ddkisdhnvw) View more | - | 24 Feb 2025 | |
Placebo+Pirtobrutinib (Treatment B: 900 mg Pirtobrutinib Matched Placebo) | srvikeccux(yjmjbbnaba) = vcfmbqgxkw xycrdiupmy (ntupayntpm, vfgqdzxsat - qoziwybnne) View more |